APO RESEARCH · REPORT
Epirubicin Hydrochloride API
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin.
Product & engineering
Understand the product.
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Its chemical name is (8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride, with the molecular formula C27H29NO11·HCl and a molecular weight of 579.98. The active moiety is a red-orange hygroscopic powder that exerts its antitumor effects through multiple mechanisms, including intercalation of its planar rings between DNA base pairs to inhibit nucleic acid and protein synthesis, stimulation of topoisomerase II-mediated DNA strand breaks, and generation of cytotoxic free radicals via redox cycling.
The API is manufactured via a semi-synthetic process that begins with microbial fermentation of appropriate Streptomyces strains to produce daunorubicin or 4'-epi-daunorubicin precursors, followed by chemical modification to invert the stereochemistry at the 4' position of the daunosamine sugar moiety. Key steps include formation of bromo-ketal intermediates, hydrolysis, oxidation, and purification through ion-exchange resins in chloride form, followed by adsorption chromatography, concentration, and final crystallization of the hydrochloride salt under controlled pH and solvent conditions to achieve pharmacopeial purity and stability.
Epirubicin hydrochloride is indicated as a component of adjuvant therapy in patients with primary breast cancer and axillary lymph node involvement following surgical resection, where it is administered intravenously in combination regimens to reduce recurrence risk. It is also used in the treatment of advanced or metastatic breast cancer and other malignancies including gastric carcinoma, ovarian carcinoma, lung carcinoma, soft-tissue sarcomas, malignant lymphomas, and certain leukemias, with dosing individualized according to body surface area and hepatic function to balance efficacy against risks of myelosuppression and cumulative cardiotoxicity.
The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.
What turns activity into demand
Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.
The commercial boundary
For Epirubicin Hydrochloride API, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.
Which conditions determine usable epirubicin hydrochloride api performance?
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.
Selected research
Industry Research
Epirubicin Hydrochloride API Industry Research Report 2026
Market perspective
Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Its chemical name is (8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride, with the molecular formula C27H29NO11·HCl and a molecular weight of 579.98. The active moiety is a red-orange hygroscopic powder that exerts its antitumor effects through multiple mechanisms, including intercalation of its planar rings between DNA base pairs to inhibit nucleic acid and protein synthesis, stimulation of topoisomerase II-mediated DNA strand breaks, and generation of cytotoxic free radicals via redox cycling.
The API is manufactured via a semi-synthetic process that begins with microbial fermentation of appropriate Streptomyces strains to produce daunorubicin or 4'-epi-daunorubicin precursors, followed by chemical modification to invert the stereochemistry at the 4' position of the daunosamine sugar moiety. Key steps include formation of bromo-ketal intermediates, hydrolysis, oxidation, and purification through ion-exchange resins in chloride form, followed by adsorption chromatography, concentration, and final crystallization of the hydrochloride salt under controlled pH and solvent conditions to achieve pharmacopeial purity and stability.
Epirubicin hydrochloride is indicated as a component of adjuvant therapy in patients with primary breast cancer and axillary lymph node involvement following surgical resection, where it is administered intravenously in combination regimens to reduce recurrence risk. It is also used in the treatment of advanced or metastatic breast cancer and other malignancies including gastric carcinoma, ovarian carcinoma, lung carcinoma, soft-tissue sarcomas, malignant lymphomas, and certain leukemias, with dosing individualized according to body surface area and hepatic function to balance efficacy against risks of myelosuppression and cumulative cardiotoxicity.
Read the full market overview
The global Epirubicin Hydrochloride API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Epirubicin Hydrochloride API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Epirubicin Hydrochloride API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Epirubicin Hydrochloride API include Synbias-Gemini, TAPI, MicroBiopharm Japan, Olon S.p.A., Sterling Biotech, Lunan Pharmaceutical, Zhejiang Hisun and DZD (Heze) Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Epirubicin Hydrochloride API market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epirubicin Hydrochloride API Market by Company
Synbias-Gemini
TAPI
MicroBiopharm Japan
Olon S.p.A.
Sterling Biotech
Lunan Pharmaceutical
Zhejiang Hisun
DZD (Heze) Pharmaceutical
Epirubicin Hydrochloride API Segment by Type
USP Grade
EP Grade
CP Grade
JP Grade
BP Grade
Others
Epirubicin Hydrochloride API Segment by Application
Injection
Freeze-dried Powder Injection
Epirubicin Hydrochloride API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epirubicin Hydrochloride API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epirubicin Hydrochloride API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epirubicin Hydrochloride API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Epirubicin Hydrochloride API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Epirubicin Hydrochloride API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Epirubicin Hydrochloride API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- USP Grade
- EP Grade
- CP Grade
- JP Grade
- BP Grade
- Others
Applications
- Injection
- Freeze-dried Powder Injection
Companies covered
- Synbias-Gemini
- TAPI
- MicroBiopharm Japan
- Olon S.p.A.
- Sterling Biotech
- Lunan Pharmaceutical
- Zhejiang Hisun
- DZD (Heze) Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Epirubicin Hydrochloride API Market Size (2021-2032)
- 2.2.2 Global Epirubicin Hydrochloride API Sales (2021-2032)
- 2.2.3 Global Epirubicin Hydrochloride API Market Average Price (2021-2032)
- 2.3 Epirubicin Hydrochloride API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 USP Grade
- 2.3.3 EP Grade
- 2.3.4 CP Grade
- 2.3.5 JP Grade
- 2.3.6 BP Grade
- 2.3.7 Others
- 2.4 Epirubicin Hydrochloride API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Injection
- 2.4.3 Freeze-dried Powder Injection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Epirubicin Hydrochloride API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Epirubicin Hydrochloride API Sales (kg) of Manufacturers (2021-2026)
- 3.3 Global Epirubicin Hydrochloride API Revenue of Manufacturers (2021-2026)
- 3.4 Global Epirubicin Hydrochloride API Average Price by Manufacturers (2021-2026)
- 3.5 Global Epirubicin Hydrochloride API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Epirubicin Hydrochloride API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Epirubicin Hydrochloride API, Product Type & Application
- 3.8 Global Manufacturers of Epirubicin Hydrochloride API, Established Date
- 3.9 Global Epirubicin Hydrochloride API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Synbias-Gemini
- 4.1.1 Synbias-Gemini Company Information
- 4.1.2 Synbias-Gemini Business Overview
- 4.1.3 Synbias-Gemini Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Synbias-Gemini Epirubicin Hydrochloride API Product Portfolio
- 4.1.5 Synbias-Gemini Recent Developments
- 4.2 TAPI
- 4.2.1 TAPI Company Information
- 4.2.2 TAPI Business Overview
- 4.2.3 TAPI Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 TAPI Epirubicin Hydrochloride API Product Portfolio
- 4.2.5 TAPI Recent Developments
- 4.3 MicroBiopharm Japan
- 4.3.1 MicroBiopharm Japan Company Information
- 4.3.2 MicroBiopharm Japan Business Overview
- 4.3.3 MicroBiopharm Japan Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 MicroBiopharm Japan Epirubicin Hydrochloride API Product Portfolio
- 4.3.5 MicroBiopharm Japan Recent Developments
- 4.4 Olon S.p.A.
- 4.4.1 Olon S.p.A. Company Information
- 4.4.2 Olon S.p.A. Business Overview
- 4.4.3 Olon S.p.A. Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Olon S.p.A. Epirubicin Hydrochloride API Product Portfolio
- 4.4.5 Olon S.p.A. Recent Developments
- 4.5 Sterling Biotech
- 4.5.1 Sterling Biotech Company Information
- 4.5.2 Sterling Biotech Business Overview
- 4.5.3 Sterling Biotech Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sterling Biotech Epirubicin Hydrochloride API Product Portfolio
- 4.5.5 Sterling Biotech Recent Developments
- 4.6 Lunan Pharmaceutical
- 4.6.1 Lunan Pharmaceutical Company Information
- 4.6.2 Lunan Pharmaceutical Business Overview
- 4.6.3 Lunan Pharmaceutical Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lunan Pharmaceutical Epirubicin Hydrochloride API Product Portfolio
- 4.6.5 Lunan Pharmaceutical Recent Developments
- 4.7 Zhejiang Hisun
- 4.7.1 Zhejiang Hisun Company Information
- 4.7.2 Zhejiang Hisun Business Overview
- 4.7.3 Zhejiang Hisun Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zhejiang Hisun Epirubicin Hydrochloride API Product Portfolio
- 4.7.5 Zhejiang Hisun Recent Developments
- 4.8 DZD (Heze) Pharmaceutical
- 4.8.1 DZD (Heze) Pharmaceutical Company Information
- 4.8.2 DZD (Heze) Pharmaceutical Business Overview
- 4.8.3 DZD (Heze) Pharmaceutical Epirubicin Hydrochloride API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 DZD (Heze) Pharmaceutical Epirubicin Hydrochloride API Product Portfolio
- 4.8.5 DZD (Heze) Pharmaceutical Recent Developments
5 Global Epirubicin Hydrochloride API Market Scenario by Region
- 5.1 Global Epirubicin Hydrochloride API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Epirubicin Hydrochloride API Sales by Region: 2021-2032
- 5.2.1 Global Epirubicin Hydrochloride API Sales by Region: 2021-2026
- 5.2.2 Global Epirubicin Hydrochloride API Sales by Region: 2027-2032
- 5.3 Global Epirubicin Hydrochloride API Revenue by Region: 2021-2032
- 5.3.1 Global Epirubicin Hydrochloride API Revenue by Region: 2021-2026
- 5.3.2 Global Epirubicin Hydrochloride API Revenue by Region: 2027-2032
- 5.4 North America Epirubicin Hydrochloride API Market Facts & Figures by Country
- 5.4.1 North America Epirubicin Hydrochloride API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 5.4.3 North America Epirubicin Hydrochloride API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Epirubicin Hydrochloride API Market Facts & Figures by Country
- 5.5.1 Europe Epirubicin Hydrochloride API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 5.5.3 Europe Epirubicin Hydrochloride API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Epirubicin Hydrochloride API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Epirubicin Hydrochloride API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Epirubicin Hydrochloride API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Epirubicin Hydrochloride API Market Facts & Figures by Country
- 5.7.1 South America Epirubicin Hydrochloride API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 5.7.3 South America Epirubicin Hydrochloride API Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Epirubicin Hydrochloride API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Epirubicin Hydrochloride API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Epirubicin Hydrochloride API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Epirubicin Hydrochloride API Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Epirubicin Hydrochloride API Sales by Type (2021-2032)
- 6.1.1 Global Epirubicin Hydrochloride API Sales by Type (2021-2032) & (kg)
- 6.1.2 Global Epirubicin Hydrochloride API Sales Market Share by Type (2021-2032)
- 6.2 Global Epirubicin Hydrochloride API Revenue by Type (2021-2032)
- 6.2.1 Global Epirubicin Hydrochloride API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Epirubicin Hydrochloride API Revenue Market Share by Type (2021-2032)
- 6.3 Global Epirubicin Hydrochloride API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Epirubicin Hydrochloride API Sales by Application (2021-2032)
- 7.1.1 Global Epirubicin Hydrochloride API Sales by Application (2021-2032) & (kg)
- 7.1.2 Global Epirubicin Hydrochloride API Sales Market Share by Application (2021-2032)
- 7.2 Global Epirubicin Hydrochloride API Revenue by Application (2021-2032)
- 7.2.1 Global Epirubicin Hydrochloride API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Epirubicin Hydrochloride API Revenue Market Share by Application (2021-2032)
- 7.3 Global Epirubicin Hydrochloride API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Epirubicin Hydrochloride API Value Chain Analysis
- 8.1.1 Epirubicin Hydrochloride API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Epirubicin Hydrochloride API Production Mode & Process
- 8.2 Epirubicin Hydrochloride API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Epirubicin Hydrochloride API Distributors
- 8.2.3 Epirubicin Hydrochloride API Customers
9 Global Epirubicin Hydrochloride API Analyzing Market Dynamics
- 9.1 Epirubicin Hydrochloride API Industry Trends
- 9.2 Epirubicin Hydrochloride API Industry Drivers
- 9.3 Epirubicin Hydrochloride API Industry Opportunities and Challenges
- 9.4 Epirubicin Hydrochloride API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst